← All Olema Pharmaceuticals, INC filings

Olema Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
OLMA
Olema Pharmaceuticals, INC
10-K: Olema Pharmaceuticals Advances Breast Cancer Therapies, Reports Losses
Olema Pharmaceuticals progresses lead product candidate palazestrant into pivotal Phase 3 trials and initiates Phase 1 for OP-3136, while reporting continued net losses for 2025.
NASDAQ
OLMA
Olema Pharmaceuticals, INC
10-K: Olema Pharmaceuticals Announces 2024 Results and Outlines Strategic Priorities
Olema Pharmaceuticals reports its 2024 financial results, highlighting progress in clinical trials for palazestrant and OP-3136, and outlines its strategic focus on developing next-generation targeted therapies for breast cancer.
NASDAQ
OLMA
Olema Pharmaceuticals, INC
10-K: Olema Pharmaceuticals Files 10-K, Highlights Progress in Cancer Therapies
Olema Pharmaceuticals' 10-K filing details the company's financial status and progress in developing targeted therapies for women's cancers, including palazestrant and OP-3136.